Brokerages Set $7.50 Price Target for EndoChoice Holdings Inc. (NYSE:GI)
EndoChoice Holdings Inc. (NYSE:GI) has received an average broker rating score of 2.75 (Hold) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and one has issued a strong buy recommendation on the company. EndoChoice Holdings’ rating score has declined by 57.1% in the last 90 days as a result of a number of analysts’ ratings changes.
Brokerages have set a 12 month consensus price target of $7.50 for the company and are forecasting that the company will post ($0.52) earnings per share for the current quarter, according to Zacks. Zacks has also given EndoChoice Holdings an industry rank of 156 out of 265 based on the ratings given to related companies.
A number of equities research analysts have weighed in on GI shares. Zacks Investment Research upgraded EndoChoice Holdings from a “hold” rating to a “buy” rating and set a $5.25 price objective for the company in a research note on Tuesday, July 5th. JPMorgan Chase & Co. initiated coverage on EndoChoice Holdings in a research report on Wednesday, July 13th. They issued an “overweight” rating for the company. William Blair lowered EndoChoice Holdings from an “outperform” rating to a “market perform” rating in a research report on Thursday, August 4th. Finally, Stifel Nicolaus decreased their target price on EndoChoice Holdings from $10.00 to $7.00 and set a “buy” rating for the company in a research report on Thursday, August 4th.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/07/brokerages-set-7-50-price-target-for-endochoice-holdings-inc-nysegi.html
EndoChoice Holdings (NYSE:GI) traded down 0.13% during mid-day trading on Friday, reaching $7.97. 422,859 shares of the company were exchanged. The stock’s 50-day moving average price is $5.02 and its 200-day moving average price is $4.85. EndoChoice Holdings has a 1-year low of $3.64 and a 1-year high of $12.44. The stock’s market capitalization is $207.59 million.
EndoChoice Holdings (NYSE:GI) last issued its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.52) by $0.47. EndoChoice Holdings had a negative net margin of 88.94% and a negative return on equity of 62.04%. The business had revenue of $19.30 million for the quarter, compared to analyst estimates of $20.67 million. During the same quarter last year, the business earned ($1.01) EPS. EndoChoice Holdings’s revenue for the quarter was up 3.8% compared to the same quarter last year. On average, equities research analysts anticipate that EndoChoice Holdings will post ($2.53) EPS for the current fiscal year.
Several hedge funds have recently made changes to their positions in the company. Iguana Healthcare Management LLC increased its stake in shares of EndoChoice Holdings by 8.7% in the second quarter. Iguana Healthcare Management LLC now owns 125,000 shares of the company’s stock valued at $613,000 after buying an additional 10,000 shares during the period. Paloma Partners Management Co bought a new stake in shares of EndoChoice Holdings during the second quarter valued at about $161,000. Bridgeway Capital Management Inc. bought a new stake in shares of EndoChoice Holdings during the second quarter valued at about $368,000. Spark Investment Management LLC bought a new stake in shares of EndoChoice Holdings during the second quarter valued at about $318,000. Finally, Vanguard Group Inc. increased its stake in shares of EndoChoice Holdings by 13.8% in the second quarter. Vanguard Group Inc. now owns 274,967 shares of the company’s stock valued at $1,348,000 after buying an additional 33,427 shares during the period. 37.71% of the stock is currently owned by institutional investors and hedge funds.
EndoChoice Holdings Company Profile
EndoChoice Holdings, Inc is a medical device company. The Company is focused on designing and commercializing a platform of products and services for gastrointestinal (GI) caregivers. The Company offers a range of products and services that span single-use devices and infection control products, pathology and imaging systems.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for EndoChoice Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EndoChoice Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.